公开(公告)号：US20210371539A1

公开(公告)日：2021-12-02

申请号：US17253276

申请日：2019-06-24

Applicant: GENMAB HOLDING B.V.

Inventor： Simone OOSTINDIE ,  Frank BEURSKENS ,  Ronald TAYLOR ,  Margaret LINDORFER ,  Hilma VAN DER HORST ,  Martine E. D. CHAMULEAU ,  Tuna MUTIS ,  Paul PARREN ,  Esther BREIJ

IPC: C07K16/28 ,  A61K45/06

Abstract: The present invention relates to anti-CD37antibodies having an Fc-Fc interaction enhancing substitution in the Fc-region of a human IgG, for use as a medicament in combination with anti-CD20 antibodies having an Fc-Fc interaction enhancing substitution in the Fc-region of a human IgG. The invention also relates to a novel composition of anti-CD37 antibodies having an Fc-Fc 5 interaction enhancing substitution and anti-CD20 antibodies having an Fc-Fc interaction enhancing substitution. In particular, the invention relates to compositions wherein the anti-CD37 antibody binds human CD37 and the anti-CD20 antibody binds human CD20. The invention also relates to compositions where the composition is a pharmaceutical composition and the use of such compositions in treatment of cancer and other diseases.

公开(公告)号：US20240252635A1

公开(公告)日：2024-08-01

申请号：US17281724

申请日：2019-10-04

Applicant: GENMAB HOLDING B.V.

Inventor： Simone OOSTINDIE ,  Frank BEURSKENS ,  Esther C. W. BREIJ ,  Edward N. VAN DEN BRINK ,  Andreas HOLLENSTEIN ,  Marije OVERDIJK ,  Margaret LINDORFER ,  Ronald TAYLOR ,  Paul PARREN ,  Hilma VAN DER HORST ,  Martine E. D. CHAMULEAU ,  Tuna MUTIS ,  Christian CIMANDER ,  Martin SAHLIN ,  Shan REN ,  Abbas RAZVI ,  Christoph GRAPENTIN

IPC: A61K39/395 ,  A61K39/00 ,  A61K47/02 ,  A61K47/18 ,  A61K47/22 ,  A61K47/26 ,  A61P35/02 ,  C07K16/28

CPC classification number: A61K39/39591 ,  A61K47/02 ,  A61K47/183 ,  A61K47/22 ,  A61K47/26 ,  A61P35/02 ,  C07K16/2887 ,  C07K16/2896 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/52 ,  C07K2317/732 ,  C07K2317/734

Abstract: The disclosure relates to pharmaceutical compositions comprising CD37-specific bispecific antibody molecules binding to different epitopes of the human CD37 antigen which bispecific antibody molecules have enhanced Fc-Fc interactions upon binding to CD37 on the cell surface. The disclosure also relates to use of these pharmaceutical compositions for the treatment of cancer and other diseases.